Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.80, $0.56 better than the analyst estimate of $5.24. Revenue for the quarter came in at $3.36 billion versus the consensus estimate of $3.26 billion.
GUIDANCE:
Biogen sees FY EPS of $24.90-$25.50 vs $24.01 consensus. FY2018 revenue of $13-13.2 billion, versus the consensus of $12.98 billion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.